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A B S T R A C T
BACKGROUND: Catheter ablation of atrial fibrillation (AF) has been increasingly used 
in experienced electrophysiology centers. A novel ablation system delivering duty-cy-
cled phased radiofrequency energy via an over-the-wire multipolar circular ablation 
catheter (PVAC™, Medtronic) to perform linear continuous ablation has been tested 
for isolation of pulmonary veins (PVs).
METHODS: Consecutive patients with indication for AF ablation have been includ-
ed. Patients underwent PV isolation using the novel ablation system and the PVAC 
catheter. PV isolation was confirmed by mapping of PV potentials using the PVAC 
catheter demonstrating entrance and exit block. Success was defined as no AF (no 
documentation of AF episodes >30 seconds during 7-day Holter EKG analysis and 
no symptomatic recurrences after a 3-month blanking period).
RESULTS: 152 patients (35 female) with a mean age of 55 (±12) years were included. 
106 patients (70%) had paroxysmal and 46 patients (30%) persistent AF. During the 
ablation procedure, 594 out of 598 (99%) PVs were effectively isolated during a mean 
procedure duration of 100 (±26) min and radiation duration of 20 (±8) min. During a 
median follow-up of 6 months, 65% of paroxysmal patients and 47% of persistent AF 
patients had no AF documented after a single ablation procedure.
CONCLUSIONS: Using a novel duty-cycled phased radiofrequency ablation system is 
effective and safe in treating AF patients. PV isolation can acutely be achieved in 99% 
of targeted veins. Mid-term success using a stringent criterion of no AF after a blank-
ing period of 3 months is 65% for paroxysmal and 47% for persistent AF patients using 
mainly PV-isolation alone.
I N T R O D U C T I O N
The number of patients with atrial fibrillation (AF) treated by non-pharmacologi-
cal options is increasing steadily.1 Using catheter ablation or surgical AF treatment, 
the pulmonary vein (PV) regions are a critical target to suppress PV foci. Therefore, 
there is a growing demand for catheter ablation systems tailored to perform fast, easy 
and effective PV isolation.1,2
Recently, an innovative radiofrequency (RF) ablation system has been introduced 
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for pulmonary vein isolation procedures. This novel system 
consists of a specifically designed decapolar circular mapping 
and ablation catheter (PVAC™ = pulmonary vein ablation 
catheter; Medtronic, USA) and a multichannel RF generator 
(Genius™; Medtronic, USA) enabling synchronous uni- and 
bipolar RF energy delivery to selected (or all) electrodes of the 
PVAC. With this novel technique contiguous nearly circular 
linear lesions can be produced. Initial studies on the acute and 
mid-term efficacy have provided excellent rhythm outcome for 
patients with paroxysmal and persistent AF.3-7
C O N C E P T S / T E C H N I Q U E
The PVAC™ (Fig. 1) is a 9-Fr. over-the-wire steerable 
catheter with 10 platinum electrodes arranged on an eccentric 
nitinol nearly circular frame. With this design tissue contact 
is unidirectional and each electrode has a thermocouple posi-
tioned towards the area of intended tissue contact. Electrodes 
are small (length 3 mm, surface area 14 mm²) and when apply-
ing a power of 10 Watts current densities equivalent to regular 
4 mm single-tip catheters are achieved. The multichannel RF 
generator GENius™ (Fig. 1) can independently deliver energy 
in unipolar and bipolar mode to any of the PVAC electrodes 
via a duty-cycle with phase differences between adjacent 
electrodes. The chosen ratio of bipolar-to-unipolar energy 
delivery (4:1, 2:1 or 1:1) tailors lesion depths (determined by 
unipolar RF ratio) and fill in between adjacent electrodes 
(determined by bipolar RF ratio). Ablations are temperature 
controlled (60°C) and limited to 8 or up to 10 Watts.3,4 Us-
ing this novel ablation system contiguous lesions of up to 80 
mm length in a nearly circular fashion can be achieved with 
a single 60-sec ablation. In 4:1-bi-to-unipolar ablation mode, 
mean lesion depth is 3.6 mm.1,4
The PVAC is an over-the-wire steerable catheter allowing 
for exact location and ablation of the targeted PV. Usually the 
PVAC (diameter 25 mm) is positioned in the antrum of the 
targeted PV and bipolar recordings of the PVAC electrodes 
display two components in sinus rhythm (SR): The first compo-
nent is left atrial local electrogram and the second component 
may be PV potentials (Fig. 2). Ablation therefore may produce 
abatement of PV potentials and also reduce local electrogram 
amplitude. This specific position of the PVAC may lead to 
problems with signal interpretation and effective PV isolation 
may only become documentable when positioning the PVAC 
deeper in the PV where no atrial far field sensing is seen. In 
addition to entrance block into the PVs during SR, exit block 
during stimulation at multiple sites within the PV can identify 
the electrophysiological endpoint of complete PV electrical 
disconnection.
R E S U L T S
So far over 3000 cases have been treated worldwide. In the 
published series of patients effective isolation of targeted PVs 
has been documented to be 93% using this single catheter ap-
proach. Nearly 85% of treated patients had effective isolation 
of all targeted PVs. Effective PV isolation has been controlled 
with conventional circumferential mapping catheters or using 
electroanatomic voltage mapping indicating complete abolish-
ment of electrical signals within the ablated regions.
The mid-term success is published to be 79.5% of mostly 
FIGURE 1. PVAC™ (A) and monitor view of the GENius™ gen-
erator (B). A - The PVAC™ catheter is an eccentric over-the-
wire catheter with 10 platinum electrodes mounted on a nitinol 
frame. B - The GENius™ generator displays measured tem-
peratures and indicates applied energy in bars for each PVAC 
electrode. Green bars indicate electrodes achieving the target 
temperature zone (55 to 65°C).
PULMONARY VEIN ISOLATION USING THE PVAC CATHETER
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FIGURE 2. Radioanatomic view and intracardiac signals during 
isolation of a right superior PV. A - Radiograph of a PVAC in 
the right superior PV (RSPV) with the wire reaching deeply into 
the vein and the PVAC being in the antral part of the PV ostium. 
B – Intracardiac signals (yellow = PVAC, green = coronary si-
nus catheter, red = right ventricular apex catheter) indicating 
PV potentials (PV) and a local atrial electrogram (A) when po-
sitioned in the ostium of the PV. After ablation () atrial 
signal show lower amplitude (a) and PV potentials are abated (* 
) indicating entrance block into the PV.
paroxysmal atrial fibrillation patients determined by 7-day 
Holter monitoring at 6 months. Procedural complications 
appear to be low (<2.0%) indicating the simplicity of the ap-
plication of the PVAC ablation device. Further studies need 
to evaluate long-term success and safety aspects are needed to 
define the role of this ablation technique in clinical practise.
In our institution 152 patients (35 female) with a mean age 
of 55(±12) years were studied. 106 patients (70%) had paroxys-
mal and 46 patients (30%) persistent AF. 594 out of 598 (99%) 
PVs were isolated during a mean procedure duration of 100 
(±26) min demonstrating entrance and exit block (radiation 
duration of 20 (±8) min and total RF energy duration of 28 
(±9) min). A mean of 8 (±3) ablation impulses (at 60 seconds) 
were needed for isolation of the left superior PV, 6 (±3) for 
the left inferior PV, 7 (±3) for the right superior and 5 (±2) 
for the right inferior PV (left common ostium 14 (±4) abla-
tion sequences). In patients with persistent AF, PV isolation 
alone was performed in 28 pts, additional ablation on the left 
sided atrial septum was done in 16, and ablation of complex 
fractionated left atrial electrograms was attempted in 7.
During a median follow-up of 6 months, 68% of parox-
ysmal patients and 49% of persistent AF patients had no AF 
documented after a single ablation procedure (no episode of 
AF in consecutive 7-day Holter recordings or symptoms sus-
ceptible of AF after a blanking-period of 3 months). Twelve 
(8%) underwent redo procedures. Five (3%) patients reported 
procedure-related groin access complications. Comparing the 
first 25 paroxysmal AF patients to the last 25 patients with 
completed follow-up there is a reduction in procedure duration 
(112±31 vs. 98±18 min) and radiation exposure (23±9 min 
vs. 18±7 min). Fifty six percent (56%) of the first and 68% 
of the last patients had no AF documented during follow-up 
indicating a learning curve with PVAC ablation.
C O N C L U S I O N S
The novel RF ablation technique using synchronous uni- 
and bipolar energy delivery via a decapolar steerable over-
the-wire mapping and ablation catheter offers potential for 
fast, safe and effective treatment of patients with symptomatic 
AF. Due to the complexity of left atrial ablation to treat AF 
including documentation of the electrophysiological endpoint 
(effective PV isolation), these procedures should be performed 
in centers with high expertise.
Unresolved issues with this new ablation system are the 
occurrence of collateral damage e.g. to the esophagus during 
PV isolation using the PVAC. In addition, when ablating within 
the left atrium without consistent cooling of the catheter tip 
(non-cooled ablation) thrombus or coagulation formation due 
to the ablation may occur. Whereas thrombus formation may 
be reduced by effective heparinization, coagulation at the 
catheter tip may not be influenced by anticoagulation because 
coagulum formation is due to direct heat-related denaturation 
of fibrinogen. Further studies need to evaluate the exact rela-
tion of the intensity of heparinization during the procedure 
and potential thromboembolic events.
Further refinements of the catheter design and technique 
(e.g. different diameters of the PVAC tip) are warranted to 
better evaluate PV isolation and further increase the efficacy 
of PVAC-based AF catheter ablation procedures.
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